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Background: Diagnosis of pheochromocytoma (PC) is based on a combination of clinical suspicion, ﬁnding an adrenal
mass, increased plasma, and urine concentrations of catecholamine metabolites and is ﬁnally conﬁrmed with histopathology.
In human medicine, it is controversial whether biochemically testing plasma is superior to testing urine.
Objectives: To measure urinary and plasma catecholamines and metanephrines in healthy dogs, dogs with PC, hypercortis-
olism (HC), and nonadrenal diseases (NAD) and to determine the test with the best diagnostic performance for dogs with PC.
Animals: Seven PC dogs, 10 dogs with HC, 14 dogs with NAD, 10 healthy dogs.
Methods: Prospective diagnostic clinical study. Urine and heparin plasma samples were collected and stored at 80°C
before analysis using high-pressure liquid chromatography (HPLC) coupled to electrochemical detection or tandem mass
spectrometry were performed. Urinary variables were expressed as ratios to urinary creatinine concentration.
Results: Dogs with PC had signiﬁcantly higher urinary normetanephrine and metanephrine : creatinine ratios and signiﬁ-
cantly higher plasma-total and free normetanephrine and plasma-free metanephrine concentrations compared to the 3 other
groups. There were no overlapping results of urinary normetanephrine concentrations between PC and all other groups, and
only one PC dog with a plasma normetanephrine concentration in the range of the dogs with HC and NAD disease. Perfor-
mances of total and free plasma variables were similar. Overlap of epinephrine and norepinephrine results between the groups
was large with both urine and plasma.
Conclusion and clinical importance: Measurement of normetanephrine is the preferred biochemical test for PC and urine
was superior to plasma.
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Pheochromocytomas (PC) are catecholamine-produc-ing tumors arising from chromaﬃn cells of the
adrenal medulla.1 Clinical signs result most often from
secretion of excessive amounts of catecholamines, and
rarely from the space-occupying or invasive nature of
the tumor.2–8 Diagnosis of PC in humans is mainly
based on biochemical detection of catecholamine-
derived secretory products. Commonly used tests are
measurement of catecholamines and their O-methoxy-
lated metabolites metanephrines (normetanephrine and
metanephrine) in 24-h urine samples or in plasma.1,9–12
The question of whether urine or plasma is best is still
somewhat controversial, but plasma metanephrines are
recommended more often as test of choice.11–16 In dogs,
evaluation of those biomarkers for the diagnosis of PC
only started a few years ago; dogs with PC, but also
those with nonadrenal illness and dogs with hypercorti-
solism (HC) can have increased catecholamines and
metanephrines excretion.17–21
PC cannot be distinguished ultrasonographically from
tumors of the adrenal cortex and there are several clini-
cal signs of PC and HC that overlap, which makes HC
an important diﬀerential diagnosis. Therefore, both,
dogs with HC and nonadrenal disease (NAD) are
important controls in the evaluation of biomarkers for
the diagnosis of PC.
Since 24-h urine sampling is impracticable, measure-
ments of urinary fractionated catecholamines and meta-
nephrines was established in spot urine samples by
expressing their concentrations as a ratio to the urinary
creatinine concentration.19 The urinary normetaneph-
rine to creatinine ratio was shown to be the parameter
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which diﬀerentiated dogs with PC best from healthy
dogs and dogs with HC.20,21 Both, free normetaneph-
rine and free metanephrine in plasma parameters were
signiﬁcantly higher in dogs with PC compared to
healthy dogs, dogs with adrenocortical tumors (AT),
and dogs with NAD; of all tested variables, plasma-free
normetanephrine discriminated best between diseases.18
No comparison between urinary and plasma variables
has been carried out in dogs.
The aim of this study was to measure urinary and
plasma catecholamines and metanephrines in healthy
dogs, dogs with PC, HC, and NAD and to determine the
test with the best discrimination for dogs with PC. With
regard to the plasma tests, an additional aim was to com-
pare the diagnostic performance of total (free + sulfo-
conjugated) and free metanephrines.
Materials and Methods
Animals
Dogs with Pheochromocytoma. Seven dogs with PC were
included; 4 of them were male (2 castrated) and 3 were spayed
females. Age ranged between 8.9 and 13 years (median 11) and body
weight between 4.1 and 22.8 kg (median 11.5). Breeds included Jack
Russell Terrier (1), West Highland White Terrier (1), Fox Terrier
(1), Cairn Terrier (1), Standard Schnauzer (1), Papillon (1), and 1
mixed-breed dog. Dogs were prospectively enrolled if diagnosis was
conﬁrmed based on histopathologic examination (4 dogs) of the
adrenal gland, an increased urinary normetanephrine to creatinine
ratio above the previously established cut-oﬀ of 4 times the upper
range of normal (3 dogs), or both.19
At presentation dogs showed various clinical signs indicative of
PC, including weakness, panting, tachycardia, agitation, trembling,
polyuria/polydipsia, abdominal pain, and signs of gastrointestinal
disease. By means of ultrasonography unilateral adrenal enlarge-
ment was identiﬁed in 5 dogs (right adrenal gland in 3 dogs, left
adrenal gland in 2 dogs), in 2 dogs bilateral adrenal enlargement
was found. In 4 dogs, diagnosis was conﬁrmed by histologic exam-
ination after adrenalectomy or by postmortem examination. Two
of these dogs were the dogs with bilateral adrenal enlargement.
Histologic examination revealed unilateral PC and contralateral
adrenocortical adenoma and bilateral adrenocortical hyperplasia,
respectively. The latter dog had a positive low-dose dexamethasone
suppression test (LDDS) and an endogenous ACTH concentration
within the reference range and was considered to be suﬀering from
concurrent pituitary-dependent hypercortisolism (PDH). In the
dog with PC and concurrent contralateral adrenocortical ade-
noma, no work up for HC had been performed. One dog that had
been presented with clinical signs highly suspicious for PC, a left-
sided adrenal mass and increased U-normetanephrine : creatinine
(497), ﬁnally was excluded, as no histopathologic examination of
the adrenal gland and no follow-up information was available to
conﬁrm the diagnosis.
Dogs with Hypercortisolism. Ten dogs with HC were included; 6
dogs were male (5 castrated) and 4 were female (3 spayed). Age ran-
ged between 6 and 15 years (median 10.5) and body weight between
7 and 40.5 kg (median 17.9). Breeds included Labrador Retriever
(1), Nova Scotia Duck Tolling Retriever (1), Dalmatian (1), York-
shire Terrier (1), Welsh Terrier (1), and 5 mixed-breed dogs.
Dogs were prospectively enrolled if clinical signs were consistent
with HC (e.g., polyuria, polydipsia, polyphagia, panting, skin
problems, weakness, abdominal enlargement), the LDDS test
yielded a positive result and owners were ready to treat and
regularly re-evaluate the dog over at least a 6-month period. PDH
was diagnosed in 5 dogs by means of a normal or increased con-
centration of endogenous ACTH, bilateral symmetrical appearance
of the adrenal gland determined by ultrasonography, demonstra-
tion of pituitary enlargement by computer tomography, or by both
the methods. All 5 dogs with PDH underwent treatment with tril-
ostane.a To minimize the risk that concurrent PC was present, as
no histopathology of the adrenal glands was available, only those
dogs with well-controlled PDH and no other clinical signs during
a minimum of 6 months after starting treatment with trilostane
were used in the study, according to our previous study
design.21,22
HC caused by an adrenocortical tumor (AT) was suspected in 5
dogs on the basis of a low endogenous ACTH concentration and
the ﬁnding of an adrenal mass by ultrasonography. AT was con-
ﬁrmed by histologic examination of the adrenal glands after adre-
nalectomy and resolution of clinical signs (3 dogs) or postmortem
examination (2 dogs). All these dogs had unilateral adrenocortical
carcinomas (right adrenal gland in 3 dogs and left adrenal gland
in 2 dogs) on histological examination. Two dogs were excluded
from the study, as either concurrent plasma and urine samples
were not available, or HC was not diagnosed intravitam (no hor-
monal tests performed). In one of the dogs, a nodular hyperplasia
of the adrenal glands and in the other canine hyperplasia of the
left adrenal and a cortical adenoma of the right adrenal gland
could be conﬁrmed on histopathology. U-normetanephrine : creat-
inine were 146 and 97, respectively in these 2 dogs.
Dogs with Nonadrenal Disease. Fourteen dogs with NAD were
included; 9 dogs were male (5 castrated) and 5 dogs were female
spayed. Age ranged between 3 and 14 years (median 7) and body
weight between 4.1 and 45 kg (median 23.8). Breeds enclosed Flat
Coated Retriever (1), Labrador Retriever (1), Manchester Terrier
(1), Border Terrier (1), Yorkshire Terrier (1), West Highland White
Terrier (1), Alaskan Malamute (1), Dachshund (1), Standard Poo-
dle (1), and 5 mixed-breed dogs. The dogs were suﬀering from dia-
betes mellitus (2), gastroenteritis (2), hepatic disease (2),
gastrointestinal foreign body (1), chronic urinary tract infection (1),
lung ﬁbrosis (1), hypothyroidism and hemangiosarcoma (1), polyar-
thritis (1), diroﬁlariasis (1), garbage intoxication (1), idiopathic
megaesophagus, and aspiration pneumonia (1). All dogs underwent
complete workup including physical examination, complete blood
count, serum biochemistry proﬁle, urinalysis, urine culture, as well
as diagnostic imaging. In all dogs, adrenal glands were either found
to be normal on ultrasonography or they showed a normal suppres-
sion of cortisol in the LDDS test (or combination of both).
Healthy Dogs. Ten healthy client-owned dogs including 5 males
(3 castrated) and 5 females (3 spayed) with a median body weight
of 26.5 kg (range, 14.6– 59.2 kg) and a median age of 5.0 years
(range, 2.0 – 7.0 years) were used. Breeds included Bernese Moun-
tain Dogs (2), Border Collie (1), Labrador Retriever (1), Golden
Retriever (1), Nova Scotia Duck Tolling Retriever (1), Rhodesian
Ridgeback (1), and 3 mixed-breed dogs. They were determined to
be healthy on the basis of history and results of physical examina-
tion, CBC, serum biochemical proﬁle, and urinalysis including
urine culture. None of the dogs had received any medication for
at least 8 weeks before inclusion in the study except routine vacci-
nation, deworming and heartworm prophylaxis.
All dogs were prospectively enrolled in the study according to the
study protocol, which was approved by the veterinary oﬃce of the
canton of Zurich and was in accordance with the guidelines and
directives established by the Animal Welfare Act of Switzerland.
Sample Collection and Processing
Urine and plasma samples for the analysis of catecholamines
and metanephrines were taken within 30 minutes during work up
in the hospital. Urine collection and processing was done as
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reported previously.19–21 In brief, 10 mL of urine were placed in a
plain silicone-coated tube containing 280 lL of 20% hydrochloric
acid (HCl). Urinary pH was measured using pH indicator stripes
(range of pH 1 – 6) and HCl was added to achieve a pH ≤2 if
needed. Samples were light-protected and stored at 80°C until
analysis. Plasma samples were collected in chilled heparin tubes,
centrifuged at 4°C, snap frozen in liquid nitrogen and stored at
80°C. Samples were shipped on dry ice to the respective labora-
tory and thawed immediately before analysis.
Measurement of Catecholamines and Metanephrines
Urine samples were analyzed at the Institute of Clinical Chemis-
try, University Hospital, Zurich, Switzerland as previously
described.19–21 Urinary norepinephrine, epinephrine, total nor-
metanephrine, and total metanephrine were quantiﬁed by HPLC
with amperometric detection as separate compounds. The term
“total” is used for the sum of free and conjugated metanephrine
according to Grouzmann et al.12 The term “metanephrines” (plu-
ral form) includes normetanephrine and metanephrine. The results
are expressed as a ratio to urinary creatinine concentrations as
reported previously19–21 and will be listed in the following sections
as: U-norepinephrine : creatinine, U-epinephrine : creatinine,
U-normetanephrine : creatinine, and U-metanephrine : creatinine.
Plasma samples were analyzed in the laboratory of the Division
of Clinical Pharmacology and Toxicology, University Hospital,
Lausanne, Switzerland. Plasma norepinephrine and epinephrine
were determined by HPLC with amperometric detection.23
Plasma-free normetanephrine and free metanephrine were quanti-
ﬁed by HPLC tandem mass spectrometry and plasma-total nor-
metanephrine and total metanephrine was measured by HPLC
with coulometric detection.9,24 Results will be listed in the
following sections as P-norepinephrine, P-epinephrine, P-total nor-
metanephrine, P-free normetanephrine, P-total metanephrine, and
P-free metanephrine.
Statistical Analysis
Data were analyzed using commercial statistical software pack-
ages.bc Descriptive statistics were calculated for quantitative vari-
ables by study group and analyzed for normality using the
Kolmogorov-Smirnov test. Analytes with non-normal distribution
in at least one group were compared using nonparametric tests.
Ranges and median values are given. The dogs with PDH and
dogs with AT were examined as one group (HC), because of the
low number of dogs. The Kruskal–Wallis test with Dunn‘s post-
test was used for comparison among groups (PC, HC, NAD,
healthy). Correlation between free and total plasma metanephrines
was analyzed by Spearman’s Rank-Order Correlation. Values of
P < .05 were considered signiﬁcant.
Results
Urinary Catecholamines and Metanephrines
U-catecholamines and U-metanephrines results for
dogs with PC, HC, nonadrenal diseases, and healthy
dogs are depicted in Table 1. U-norepinephrine : creati-
nine and U-epinephrine : creatinine did not diﬀer
between dogs with PC and dogs with HC, however, U-
norepinephrine : creatinine was signiﬁcantly higher in
dogs with PC than in dogs with NAD and healthy
dogs.
U-normetanephrine : creatinine and U-metaneph-
rine : creatinine were signiﬁcantly higher in dogs with
PC compared to the dogs in the other 3 groups (Fig 1).
U-normetanephrine : creatinine ratios in 7 PC dogs
(≥467, minimum) did not overlap with those of HC
dogs (≤300, maximum), NAD dogs (≤208, maximum),
or healthy dogs (≤123, maximum); however U-meta-
nephrine : creatinine of 2 and 3 PC dogs overlapped
with those of HC (≤145, maximum) and NAD (≤342,
maximum) dogs, respectively. If present, statistically sig-
niﬁcant diﬀerences between dogs with HC, NAD, and
healthy dogs of all urinary variables are indicated in
Table 1.
Plasma Catecholamines and Metanephrines
P-catecholamines and P-metanephrines results of dogs
with PC, HC, NAD and healthy dogs are depicted in
Table 1. There was a marked overlap in P-epinephrine
and P-norepinephrine among the results of all groups.
P-total and free normetanephrine were signiﬁcantly
higher in dogs with PC compared to dogs with HC,
NAD, and healthy dogs. The P-total and P-free nor-
metanephrine concentrations in only 1 of the 7 PC dogs
overlapped with concentrations found in HC and NAD
dogs.
P-total metanephrine was not diﬀerent in dogs with
PC compared to HC dogs; however, there was a signiﬁ-
cant diﬀerence compared to NAD and healthy dogs.
P-free metanephrine was signiﬁcantly higher in PC dogs
compared to dogs of all other groups. P-total meta-
nephrine and P-free metanephrine of 3 and 4 PC dogs
overlapped with those of HC and NAD dogs, respec-
tively. If present, statistically signiﬁcant diﬀerences
between dogs with HC, NAD, and healthy dogs of all
plasma variables are indicated in Table 1.
Fig. 1. Urinary normetanephrine to creatinine ratios in dogs with
pheochromocytoma (PC, n = 7), dogs with hypercortisolism (HC,
n = 10), dogs with nonadrenal diseases (NAD, n = 14) and in
healthy dogs (n = 10). Horizontal bars represent median values.
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Comparison between Free and Total Plasma Results
There was a signiﬁcant positive correlation between
P-free normetanephrine and P-total normetanephrine
(r = 0.91, P < .001) as well as between P-free metaneph-
rine and P-total metanephrine (r = 0.83, P < .001).
Discussion
We were able to show that the determination of
metanephrine and normetanephrine (plasma and urine)
was superior in diﬀerentiating dogs with PC from dogs
with HC and NAD compared to epinephrine and nor-
epinephrine. Our results conﬁrm earlier studies in which
catecholamines and their metabolites were evaluated in
dogs with PC and other diseases.18,21 Measurement of
the catecholamine metabolites in urine or plasma sam-
ples in human medicine has become the biochemical test
of choice in the diagnosis of PC.1,25 The main reason is
that catecholamines are rapidly metabolized into meta-
nephrines within the tumor, and the latter are continu-
ously released into the circulation.11,15,26
In this study, U-normetanephrine : creatinine was the
best variable to diﬀerentiate between PC, HC and
NAD, consistent with earlier studies.19–21 Normetaneph-
rine was clearly superior to metanephrine. This was true
for the urine as well as for the plasma test and is most
likely because of the fact that canine PCs produced
more norepinephrine than epinephrine. One might
therefore consider limiting testing to normetanephrine.
However, the number of dogs with PC in which meta-
nephrines have been evaluated is still quite small.
Although it has not been shown in dogs yet, it is possi-
ble that some PCs predominantly produce epinephrine
(which is metabolized to metanephrine), as has been
described in humans.27 Those would be missed if only
normetanephrine were to be measured.
HC is a diﬀerential diagnosis for PC: Both diseases
might have similar clinical signs such as weakness, tac-
hypnea, panting, polydipsia/polyuria, hypertension, as
well as similar abnormalities of the adrenal glands
detected via ultrasonography.21 Because some overlap
in U-normetanephrine : creatinine between PC and HC
was found in our earlier study, we recommended using
a cut-oﬀ value of 4 times the upper limit of normal.21
In human medicine, it has been shown that by working
with a cut-oﬀ value of 4 times the upper limit of normal
the probability of a PC is nearly 100%.1
In this study, the calculated cut-oﬀ value of 4 times
normal was somewhat higher than in our previous
study (492 versus 364).21 Using the cut-oﬀ value of the
present study, one of the dogs with PC would have
been missed. This means that diagnostic sensitivity
would decrease if the cut-oﬀ were changed. Comparing
the ages of the healthy dogs in the earlier study21 with
those of the healthy dogs in this study revealed a sig-
niﬁcant diﬀerence between the two in that the latter
were signiﬁcantly younger (P = .002; data not shown).
From human medicine, it is known that free plasma
normetanephrine is inﬂuenced by age and that age-
adjusted cut-oﬀs of reference intervals improve diagnos-
tic performance.28 The population that is used for
establishing reference intervals is important. Reference
interval in general, or in our case cut-oﬀ values, should
best be established in a population with an age range
in which the disease is expected to occur, and PCs are
expected to occur predominantly in middle-aged to
older dogs.
In urine, total (conjugated + free) metanephrines are
measured, whereas in plasma measurement of both free
and total as separate tests is available. Recently, the
measurement of free metanephrines in plasma was
described in veterinary medicine.18 Determination of
P-free normetanephrine was superior to P-free meta-
nephrine to diﬀerentiate dogs with PC from dogs with
HC and dogs with NAD. There was only a moderate
overlap between the groups. The results presented here
approximate those ﬁndings. P-free normetanephrine and
P-free metanephrine were signiﬁcantly higher in dogs
with PC compared to the other groups and overlap was
clearly less for P-free normetanephrine.
The measurement of P-total metanephrines is analyti-
cally easier than measurement of P-free metanephrines,
because they are rather stable and appear in plasma in
higher concentrations.9,29,30 In humans it was shown
that the sensitivity and speciﬁcity of plasma-total and
plasma-free metanephrines is similar.9 In our study, per-
formance of P-total and P-free parameters compared
Table 1. Ranges and median values of urinary catecholamines and metanephrines to creatinine ratios, plasma cate-
cholamines and plasma-total and free metanephrines in dogs with pheochromocytoma (PC), with hypercortisolism
(HC), with nonadrenal diseases (NAD), and in healthy dogs.
Parameter PC HC NAD Healthy
U-norepinephrine : creatinine 8.0–2687.0 (44.0)a 7.0–31.0 (14.5)a 2.0–26.0 (8.0)b 3.0–17.0 (4.5)b
U-epinephrine : creatinine 2.0–914.0 (13.0) 2.0–25.0 (7.5) 1.0–47.0 (6.0) 1.0–18.0 (3.0)
U-normetanephrine : creatinine 467.0–12472.0 (2137.0)a 68.0–300.0 (147.0)b 34.0–208.0 (99.5)b 26.0–123.0 (56.0)c
U-metanephrine : creatinine 134.0–4576.0 (1381.5)a 31.0–145.0 (56.5)b 28.0–343.0 (63.5)b 12.0–65.0 (31.5)c
P-norepinephrine (nmol/L) 1.1–108.0 (7.6)a 1.8–7.0 (2.3)a,b 0.6–5.1 (1.9)b,c 0.9–2.2 (1.6)c
P-epinephrine (nmol/L) 0.1–368.0 (0.7) 0.1–1.4 (0.6) 0.2–2.9 (0.8) 0.3–1.2 (0.7)
P-total normetanephrine (nmol/L) 6.5–673.0 (24.4)a 2.4–15.0 (6.3)b 2.2–7.2 (4.6)b,c 2.8–5.4 (3.1)c
P-free normetanephrine (nmol/L) 3.3–211.0 (11.8)a 1.5–6.6 (2.6)b 1.0–4.0 (2.4)b 0.9–-2.1 (1.4)c
P-total metanephrine (nmol/L) 1.6–241.0 (6.4)a 0.3–4.2 (2.0)a,b 0.5–6.3 (1.6)b,c 0.4–2.2 (1.4)b,c
P-free metanephrine (nmol/L) 1.0–102.0 (3.8)a 0.4–1.7 (1.2)b 0.5–4.1 (1.1)b 0.3–1.2 (0.8)b
Diﬀerent letters indicate statistically signiﬁcant diﬀerences between the groups (P < .05).
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very well and the number of dogs with PC having
concentrations within the range of dogs with HC was
identical. Account has to be taken of the fact that the
P-total metanephrines are eliminated in the urine, there-
fore false high values can be expected if renal function
is impaired. Because P-free metanephrines are relatively
independent from renal function, they are more suitable
in cases of renal failure27; however, this issue has yet to
be evaluated in dogs.
Nonadrenal illness can increase the production of
catecholamines and metanephrines.17,31–33 The impact
of nonadrenal diseases can vary according to their
severity. To circumvent the problem of false positive
results the use of the above-mentioned cut-oﬀ values of
4 times normal is helpful. One should be aware, how-
ever, that in using this cut-oﬀ value PC might be missed
because of decreased diagnostic sensitivity. If diagnostic
sensitivity is high, diagnosis can be excluded based on a
negative test result; on the other hand, the higher the
sensitivity of a test in a biological setting, the lower its
speciﬁcity, meaning more false positive results. The
most important clinical task is to diﬀerentiate dogs with
PC from those with HC or other pathologies that may
look like PC. A cut-oﬀ point above which PC is likely
even in the face of other diseases should be determined.
It is worth noting that concurrent HC and PC did not
have an inﬂuence on catecholamine metabolite excre-
tion, as concentrations of the 2 dogs with both diseases
did not diﬀer from the other dogs in the PC group, and
signiﬁcance between the groups did not change when
these 2 dogs were excluded from statistical analysis
(data not shown).
The main limitation of our study is the lack of a gold
standard with which the true function of the adrenal
gland can be determined. We cannot exclude that we
have missed more dogs with PC, as the same method
was used as a ‘gold standard’ (cut-oﬀ of 4 times U-nor-
metanephrine : creatinine of healthy dogs) and was at
the same time being evaluated, although during the
study period we did not have dogs with values in the
“gray-zone” that were excluded. Obtaining histopathol-
ogy on all animals is diﬃcult and often impractical in a
clinical setting.
In human medicine there is some controversy as to
which test (urine or plasma) has the higher diagnostic
accuracy for PC. Several authors have demonstrated a
higher sensitivity of P-free metanephrines compared to
U-metanephrines.10,11,15 The speciﬁcity of the plasma
test has been claimed to be lower; however, the various
studies are diﬃcult to compare because of diﬀerences in
design.
In this study, U-normetanephrine : creatinine diﬀer-
entiated dogs with PC from dogs with HC and dogs
with NAD without any overlap, whereas with regard to
P-normetanephrines, there was some overlap among the
groups. However, as we did ﬁnd some overlap in our
previous studies, this is a coincidental ﬁnding.20,21
Moreover, it is likely that the overlap among the diﬀer-
ent groups of U-normetanephrine : creatinine ratios
and also of the other parameters would have been more
extensive using higher numbers of dogs.
In conclusion, determination of normetanephrine
seems the best parameter to diﬀerentiate between dogs
with PC and those with other diseases. So far no rec-
ommendation on whether to test urine or plasma can
be made; therefore until more studies have been per-
formed, the decision should be based on available tech-
nical facilities and the availability of dog-speciﬁc
reference ranges.
Footnotes
a Vetoryl, MSD Animal Health GmbH, Luzern, CH
b IBM SPSS, Software Packets for Macintosh, Version 19
c GraphPad PRISM for Macintosh, Version 6
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